FDA Drug Storage Temperature Requirements: Ranges and Penalties

FDA drug storage temperature requirements are set by the label on each drug product and enforced through federal regulations at 21 CFR Parts 210, 211, and 205. The default range, controlled room temperature, is 20°C to 25°C (68°F to 77°F). Refrigerated drugs must be held at 2°C to 8°C (36°F to 46°F), frozen drugs at −25°C to −10°C (−13°F to 14°F), and some advanced therapies at −70°C or below. A drug held outside its labeled range is legally “adulterated” and cannot be sold, and everyone in the supply chain from manufacturer to pharmacy is responsible for keeping it in range.

The Required Temperature Ranges

Manufacturers set the correct storage temperature for each product through stability studies and put that information on the label. The FDA relies on the definitions published by the United States Pharmacopeia (USP) for the standard ranges:

Controlled room temperature (CRT): 20°C to 25°C (68°F to 77°F). This is the default for most solid oral medications, including tablets and capsules. Temporary excursions between 15°C and 30°C (59°F and 86°F) are permitted in pharmacies, warehouses, and during transport, as long as the product’s quality isn’t compromised. Brief exposure up to 40°C (104°F) may be tolerable if the mean kinetic temperature stays at or below 25°C.
Refrigerated (cold): 2°C to 8°C (36°F to 46°F). This range covers many vaccines, insulin products, and certain biologics. Even a few hours outside this window can permanently degrade some of these products.
Frozen: −25°C to −10°C (−13°F to 14°F). Some biologics and specialty medications require frozen storage to maintain stability.
Ultra-cold: Some advanced therapies, including certain mRNA vaccines and cell-based treatments, require temperatures as low as −70°C or below. These products come with manufacturer-specific handling protocols that go well beyond standard frozen storage.

When no storage instruction appears on a drug’s labeling, controlled room temperature applies by default under 21 CFR 205.50.¹

Why These Ranges Are Legally Enforceable

Two layers of federal law make label temperatures binding. The statute, Section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act, declares a drug “adulterated” if the facilities or controls used for its manufacturing, processing, packing, or holding don’t conform to current good manufacturing practice.² Selling an adulterated drug is illegal.

The regulations at 21 CFR Parts 210 and 211 give that statute its detail. Part 211 requires that drug products be stored “under appropriate conditions of temperature, humidity, and light so that the identity, strength, quality, and purity of the drug products are not affected.”³ For wholesale distributors, 21 CFR 205.50 separately requires that all prescription drugs be stored at temperatures matching either the product’s labeling or the current USP/National Formulary.¹

Monitoring, Calibration, and Mapping

Meeting the temperature range is only half the obligation. You also have to prove you met it. In practice this means continuous monitoring, usually with digital data loggers that record at set intervals and trigger alarms when readings drift out of range.

Under 21 CFR 211.68, any automatic, mechanical, or electronic equipment used to hold a drug product must be “routinely calibrated, inspected, or checked according to a written program designed to assure proper performance,” with written records of those checks.⁴ The regulation doesn’t set a fixed calibration interval; it requires you to have a written plan appropriate to the equipment and to follow it. Calibration must be traceable to recognized national standards, meaning your sensor’s accuracy has to link back through documentation to a reference standard from an accredited source.

Before a monitoring probe can represent an entire storage area, the area itself needs to be shown to hold uniform temperatures. Temperature mapping does that job. Multiple calibrated sensors are placed throughout a storage room, warehouse, or refrigerator for an extended period, typically across seasons or load conditions, to identify hot spots and cold spots. The results tell you where to place permanent probes (in the locations with the greatest variability, not the convenient ones) and confirm the space can actually maintain the labeled range. Mapping should be repeated after any significant change to the space or HVAC system and periodically thereafter.

What to Do When Temperature Goes Out of Range

A temperature excursion means monitoring data shows the storage environment moved outside the defined limits. The response has to be structured.

Quarantine comes first. Any product exposed to the excursion is physically separated and labeled so it cannot be dispensed or shipped while under review. The investigation then determines the root cause (equipment failure, door left open, power loss), the duration of the excursion, and the temperature extremes reached. That work usually involves consulting the drug’s manufacturer, who holds the stability data needed to judge whether the product remains safe and effective.

The stability assessment is where the outcome is decided. Mean kinetic temperature, a USP tool that converts a fluctuating temperature history into a single “effective” temperature, is often used at this stage together with the manufacturer’s stability profile. USP recommends calculating MKT over the most recent 30 days of data for CRT products and 24 hours for refrigerated products; using a longer window after an excursion dilutes its impact and can hide a real problem. Every step of the investigation and the disposition decision needs thorough documentation.

When Product Cannot Be Salvaged

The regulations draw a hard line for extreme exposures. Under 21 CFR 211.208, drug products subjected to temperature extremes from natural disasters, fires, accidents, or equipment failures cannot be returned to the marketplace unless laboratory testing confirms the product still meets all standards for identity, strength, quality, and purity, and inspection confirms the packaging wasn’t compromised.⁵ Visual inspection is not enough. If the product looks fine but you cannot produce lab data proving it meets specifications, it must be destroyed.

Reporting Biological Product Deviations

Most excursions are handled through internal investigation and documentation. Biological products have a separate reporting duty. If a temperature deviation may have affected the safety, purity, or potency of a biological product that has already been distributed, the manufacturer must file a Biological Product Deviation report with the FDA within 45 calendar days of discovering the event.⁶ The trigger is distribution. Catch and correct the problem before shipment and no report is required; once the product has left the facility, the reporting clock starts.

Records You Have to Keep

Temperature records are subject to the same retention rules as other batch records. Under 21 CFR 211.180, production, control, and distribution records tied to a specific batch must be retained for at least one year after the batch’s expiration date. For certain over-the-counter products without expiration dates, retention is three years after distribution.⁷

If those records are electronic, 21 CFR Part 11 also applies. Systems must be validated to produce accurate records, must maintain secure audit trails that timestamp entries and cannot be altered without leaving a trace, and must limit access to authorized personnel. Electronic signatures must be unique to each individual and linked to their records so they cannot be copied or transferred.⁸ A monitoring system that lets anyone log in with a shared password and delete records without an audit trail has a Part 11 problem stacked on top of a cGMP problem.

Responsibility Across the Supply Chain

Temperature requirements do not end at the manufacturer’s loading dock. The obligation to maintain labeled storage conditions follows the product through every warehouse, distribution center, and delivery vehicle until it reaches the patient.

The manufacturer conducts the stability studies and sets the label. That label then governs every downstream handler. Distributors and wholesalers must maintain appropriate conditions during both warehousing and transport, using validated cold chain packaging, insulated containers, or climate-controlled vehicles as the product requires.¹ Every handoff is a vulnerability. Shipments moving from a climate-controlled truck onto an ambient loading dock, or pharmacy deliveries waiting at a back entrance, create excursion risk that documentation at each transfer point should capture. The Drug Supply Chain Security Act reinforces these obligations and references USP guidelines as the benchmark.

The final link is the pharmacy or clinic. A refrigerated product left on a counter during a busy shift, or a freezer that fails overnight, triggers the same investigation and documentation obligations that apply at every other point in the chain. Where returned products raise any doubt about proper storage, 21 CFR 205.50 requires destruction or return to the supplier unless testing confirms the product still meets all quality standards.

Penalties for Violations

Enforcement usually starts with an FDA Form 483 issued at the end of an inspection. Common temperature-related citations include gaps in monitoring logs and inadequate drug accountability records. Depending on the response and severity, the outcome can range from no action to a Warning Letter identifying serious deviations that require immediate correction. If those don’t produce results, the FDA can seek a court order to seize adulterated products or an injunction ordering the company to stop violating cGMP, often with court-supervised corrective action plans.⁹

Criminal penalties sit at the top. A first violation of the Federal Food, Drug, and Cosmetic Act is a misdemeanor carrying up to one year in prison and a fine of up to $1,000. A second conviction, or a violation committed with intent to mislead, becomes a felony punishable by up to three years in prison and fines up to $10,000. Knowingly adulterating a drug in a way that creates a reasonable probability of serious health consequences or death carries a maximum of 20 years in prison and a fine of up to $1,000,000.¹⁰

1
eCFR. 21 CFR 205.50 – Minimum Requirements for the Storage and Handling of Prescription Drugs
2
Office of the Law Revision Counsel. 21 U.S. Code 351 – Adulterated Drugs and Devices
3
eCFR. 21 CFR Part 211 Subpart H – Holding and Distribution
4
eCFR. 21 CFR 211.68 – Automatic, Mechanical, and Electronic Equipment
5
eCFR. 21 CFR 211.208 – Drug Product Salvaging
6
U.S. Food and Drug Administration. Guidance for Industry: Biological Product Deviation Reporting for Licensed Manufacturers of Biological Products Other Than Blood and Blood Components
7
eCFR. 21 CFR 211.180 – General Requirements
8
eCFR. 21 CFR Part 11 – Electronic Records; Electronic Signatures
9
U.S. Food and Drug Administration. Facts About the Current Good Manufacturing Practice (CGMP)
10
Office of the Law Revision Counsel. 21 USC 333 – Penalties